ATE474856T1 - Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen - Google Patents

Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen

Info

Publication number
ATE474856T1
ATE474856T1 AT05816060T AT05816060T ATE474856T1 AT E474856 T1 ATE474856 T1 AT E474856T1 AT 05816060 T AT05816060 T AT 05816060T AT 05816060 T AT05816060 T AT 05816060T AT E474856 T1 ATE474856 T1 AT E474856T1
Authority
AT
Austria
Prior art keywords
antibodies
binding partners
inflammation
antagonizing
present
Prior art date
Application number
AT05816060T
Other languages
English (en)
Inventor
Wenfeng Xu
Wayne Kindsvogel
Yasmin Chandrasekher
Stacey Dillon
Joyce Lehner
Anthony Siadak
Pallavur Sivakumar
Margaret Moore
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE474856T1 publication Critical patent/ATE474856T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
AT05816060T 2004-10-22 2005-10-21 Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen ATE474856T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62155304P 2004-10-22 2004-10-22
PCT/US2005/037821 WO2006047249A1 (en) 2004-10-22 2005-10-21 Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
ATE474856T1 true ATE474856T1 (de) 2010-08-15

Family

ID=35871017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05816060T ATE474856T1 (de) 2004-10-22 2005-10-21 Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen

Country Status (21)

Country Link
US (5) US7537761B2 (de)
EP (1) EP1812476B1 (de)
JP (1) JP4898691B2 (de)
KR (1) KR101238684B1 (de)
CN (1) CN101198625A (de)
AT (1) ATE474856T1 (de)
AU (1) AU2005299809B2 (de)
BR (1) BRPI0516975A (de)
CA (1) CA2584157C (de)
CY (1) CY1110843T1 (de)
DE (1) DE602005022475D1 (de)
DK (1) DK1812476T3 (de)
EA (1) EA015706B1 (de)
ES (1) ES2347672T3 (de)
IL (2) IL182503A (de)
MX (1) MX2007004770A (de)
NO (1) NO20072602L (de)
PT (1) PT1812476E (de)
UA (1) UA96122C2 (de)
WO (1) WO2006047249A1 (de)
ZA (1) ZA200704125B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
EP2177616B1 (de) * 2000-08-08 2012-02-29 ZymoGenetics, Inc. Lösliche Zcyctor 11 Cytokinrezeptoren
AU2004223837C1 (en) * 2003-03-24 2012-03-15 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2005052000A2 (en) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
WO2007126439A2 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2011047153A1 (en) * 2009-10-15 2011-04-21 President And Fellows Of Harvard College Methods for modulating autoimmunity
PH12012500924A1 (en) 2009-11-19 2012-11-26 Merck Serono Sa Humanized antibodies against human il-22ra
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
AU2012204574B2 (en) 2011-01-04 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating age-related macular degeneration
EP2686347B1 (de) 2011-03-16 2018-05-02 argenx BVBA Antikörper gegen cd70
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017181143A1 (en) * 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
EP3464357A1 (de) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von bakteriellen lungeninfektionen
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
CN110402393A (zh) * 2016-11-24 2019-11-01 休伯特保健公司 疾病诊断的组合物
US11279755B2 (en) 2017-04-25 2022-03-22 Lbl Biotechnology, Inc. Use of IL-20 antagonists for treating eye diseases
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
KR20210019464A (ko) 2018-06-05 2021-02-22 바이오아트라, 인코퍼레이티드 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도
CN110078832B (zh) * 2019-04-18 2021-12-14 江南大学 一类基于ZZ domain的二抗及其制备方法和应用
EP4106794A4 (de) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd Verfahren zum behandeln der transplant-und-wirts-krankheit
KR20230165212A (ko) * 2021-03-02 2023-12-05 다나-파버 캔서 인스티튜트 인크. 적혈구 장애의 치료 방법
WO2024184333A1 (en) 2023-03-08 2024-09-12 Leo Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
EP0154316B1 (de) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
NZ212437A (en) 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
EP0912734B1 (de) 1996-07-12 2010-11-03 Genentech, Inc. Chimärische heteromultimerische adhesine
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO2000012708A2 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
WO1999003982A1 (en) 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
EP1009762A2 (de) 1997-08-06 2000-06-21 ZymoGenetics, Inc. Lipocalinhomologen
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
AU739420B2 (en) 1997-11-26 2001-10-11 Zymogenetics Inc. Mammalian cytokine-like polypeptide-10
US6576743B1 (en) 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
ES2226335T3 (es) 1998-01-23 2005-03-16 Immunex Corporation Receooctires de uk.18.
EP1062332A2 (de) 1998-03-09 2000-12-27 Schering Corporation Menschliche rezeptorproteine; und verwandte reagenzien und verfahren
EP1490386B1 (de) 1998-03-10 2008-08-13 Genentech, Inc. Neuartiges polypeptid und dessen kodierende nukleinsäuren
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999061630A2 (en) 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
CN1238367C (zh) 1998-10-26 2006-01-25 路德维格癌症研究院 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
EP1141008A1 (de) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Cytokinin klasse ii rezeptor-ähnliche proteine und für diese kodierende nukleinsäuren
ES2295026T3 (es) 1999-04-28 2008-04-16 Genetics Institute, Llc Proteinas gil-19/ae289 humanas y polinucleotidos que codifican las mismas.
AU5151100A (en) 1999-05-19 2000-12-05 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
EP1208195A2 (de) 1999-06-15 2002-05-29 Genentech Inc. Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäure
ES2286029T3 (es) 1999-07-07 2007-12-01 Zymogenetics Inc Receptor de citocina humano.
CA2380355A1 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA02005058A (es) 1999-11-18 2002-11-07 Schering Corp Proteinas de mamiferos receptoras, reactivos y metodos relacionados.
EP1234035B1 (de) 1999-12-03 2010-02-24 ZymoGenetics, Inc. Menschliches zytokinrezeptor
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
DK1246846T3 (da) 1999-12-23 2008-12-08 Zymogenetics Inc Oplöselig interleukin-20-receptor
WO2001046422A1 (en) 1999-12-23 2001-06-28 Zymogenetics, Inc. Novel cytokine zcyto18
WO2001046261A1 (en) 1999-12-23 2001-06-28 Zymogenetics, Inc. Method for treating inflammation
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
EP2177616B1 (de) 2000-08-08 2012-02-29 ZymoGenetics, Inc. Lösliche Zcyctor 11 Cytokinrezeptoren
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
WO2002022153A2 (en) 2000-09-15 2002-03-21 Zymogenetics, Inc. Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
EP1191035A3 (de) 2000-09-25 2002-04-17 Schering Aktiengesellschaft Drei Mitglieder der Zytokinrezeptorfamilie Klasse II
US20030022827A1 (en) 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
NZ527087A (en) 2001-01-12 2008-09-26 Genetics Inst Llc Type 2 cytokine receptor and nucleic acids encoding same
EP1390060A2 (de) 2001-01-26 2004-02-25 Eli Lilly And Company Verwendung von lp82 zur behandlung von störungen des körpergewichtes
JP2005510451A (ja) 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー 炎症性障害を治療するための組成物及び方法
US7101539B2 (en) 2001-02-28 2006-09-05 Eli Lilly And Company Use of LP82 to treat hematopoietic disorders
JP2004532624A (ja) 2001-03-02 2004-10-28 ザイモジェネティクス，インコーポレイティド マウスサイトカイン受容体
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
ATE432942T1 (de) 2001-03-09 2009-06-15 Zymogenetics Inc Löslicher heterodimerer cytokinrezeptor
CA2439961A1 (en) 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
DE60234094D1 (de) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
WO2003035096A1 (en) 2001-10-22 2003-05-01 Eli Lilly And Company Soluble proteins that inhibit cytokine signal transduction pathways
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
AU2002357283B2 (en) 2001-12-17 2007-08-16 Zymogenetics, Inc. Method for treating cervical cancer
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
AU2004223837C1 (en) * 2003-03-24 2012-03-15 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2005052000A2 (en) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
PH12012500924A1 (en) * 2009-11-19 2012-11-26 Merck Serono Sa Humanized antibodies against human il-22ra

Also Published As

Publication number Publication date
US7537761B2 (en) 2009-05-26
EP1812476B1 (de) 2010-07-21
US20090220519A1 (en) 2009-09-03
MX2007004770A (es) 2007-11-22
CN101198625A (zh) 2008-06-11
UA96122C2 (ru) 2011-10-10
CA2584157C (en) 2014-10-14
US20100210825A1 (en) 2010-08-19
ES2347672T3 (es) 2010-11-03
DK1812476T3 (da) 2010-10-25
WO2006047249A1 (en) 2006-05-04
BRPI0516975A (pt) 2008-09-30
US8124088B2 (en) 2012-02-28
HK1110333A1 (en) 2008-07-11
JP2008517922A (ja) 2008-05-29
US8536309B2 (en) 2013-09-17
IL182503A (en) 2012-01-31
KR101238684B1 (ko) 2013-03-04
KR20070084486A (ko) 2007-08-24
AU2005299809A1 (en) 2006-05-04
AU2005299809A2 (en) 2006-05-04
CA2584157A1 (en) 2006-05-04
DE602005022475D1 (de) 2010-09-02
JP4898691B2 (ja) 2012-03-21
EA200700916A1 (ru) 2007-10-26
US7871616B2 (en) 2011-01-18
IL207146A (en) 2012-06-28
IL182503A0 (en) 2007-09-20
AU2005299809B2 (en) 2010-12-02
PT1812476E (pt) 2010-11-08
IL207146A0 (en) 2010-12-30
ZA200704125B (en) 2008-09-25
EA015706B1 (ru) 2011-10-31
US20130315919A1 (en) 2013-11-28
US20120156210A1 (en) 2012-06-21
CY1110843T1 (el) 2015-06-10
EP1812476A1 (de) 2007-08-01
NO20072602L (no) 2007-07-23
US20060141582A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
ATE474856T1 (de) Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
ATE475673T1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
MXPA06014465A (es) Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
WO2005052001A3 (en) Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
DE602007006429D1 (de) Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen
DE602006016965D1 (de) Il-17a- und il-17f-antagonisten und verwendungsverfahren
EP1603949B8 (de) Antikörper gegen il21-rezeptor und deren verwendung
WO2009082624A3 (en) Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
MY146664A (en) Antibodies against human il-22 and uses therefor
WO2008133684A8 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
MY149448A (en) Interleukin-21 receptor binding proteins
EA200700823A1 (ru) Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1812476

Country of ref document: EP